Hans Ibsen Selected Research

Hypertension (High Blood Pressure)

06/2008	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
02/2007	Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
08/2006	N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
03/2006	Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
11/2005	Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
11/2005	Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
09/2005	The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
05/2005	Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
04/2005	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
04/2005	Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
04/2005	Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
03/2005	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
03/2005	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
03/2005	The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
02/2005	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
01/2005	Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
01/2005	Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
09/2004	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
09/2004	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
08/2004	N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
01/2003	[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]
09/2002	Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
09/2002	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
09/2002	Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.
06/2002	[How do we find the patients with renal artery stenosis and hypertension who benefit from percutaneous transluminal angioplasty?]
05/2002	Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.
03/2002	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Articles by Research Topic

Disease

28	Hypertension (High Blood Pressure) 06/2008 - 03/2002
14	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 06/2008 - 02/2002
4	Albuminuria 03/2006 - 09/2004
3	Stroke (Strokes) 03/2005 - 01/2005
2	Syndrome 12/2006 - 10/2005
2	Atrial Fibrillation 03/2005 - 03/2005
1	Bundle-Branch Block (Fascicular Block) 06/2008
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2006
1	Carotid Stenosis (Carotid Artery Stenosis) 03/2006
1	Sclerosis 11/2005
1	Hypertrophy 01/2005
1	Cardiomegaly (Heart Hypertrophy) 01/2005
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 08/2003
1	Vascular Diseases (Vascular Disease) 08/2003
1	Diabetes Mellitus 01/2003
1	Renal Artery Obstruction (Renal Artery Stenosis) 06/2002

Drug/Important Bio-Agent (IBA)

29	Losartan (Cozaar)FDA Link 06/2008 - 03/2002
17	Atenolol (Tenormin)FDA LinkGeneric 03/2006 - 03/2002
3	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2006 - 08/2004
1	LDL CholesterolIBA 12/2006
1	C-Reactive ProteinIBA 08/2006
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2005
1	AngiotensinsIBA 11/2005
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2005
1	Natriuretic PeptidesIBA 05/2005
1	Insulin (Novolin)FDA Link 04/2005
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 03/2005
1	CreatinineIBA 02/2002

Therapy/Procedure

1	Balloon Angioplasty (Angioplasty, Transluminal) 06/2002